EPA and DHA Pre-treatment for Chemotherapy Cell Membrane Protection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current cancer therapies, such as chemotherapy and radiation therapy, often cause severe side effects in patients due to the damage inflicted on healthy cells, limiting the dosage and effectiveness of treatments.

Innovation Solution

Administration of a composition comprising omega-3 fatty acids, specifically EPA and DHA, before the start of a chemotherapy or radiation therapy cycle to improve treatment effectiveness and mitigate side effects by incorporating these fatty acids into cell membranes, thereby protecting healthy cells from therapy-induced toxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapy or radiation therapy is administered to treat cancer, then the effectiveness of cancer treatment is improved, but severe side effects occur due to damage to healthy cells

Engineering Contradiction:
Improveeffectiveness of cancer treatmentVSAvoidside effects on healthy cells
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by administering omega-3 fatty acids (EPA and DHA) before the start of chemotherapy or radiation therapy cycles. This pre-treatment allows the fatty acids to be incorporated into cell membranes in advance, creating a protective effect that mitigates subsequent therapy-induced damage to healthy cells while maintaining treatment effectiveness

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent uses omega-3 fatty acids as an intermediary substance that mediates between the chemotherapy/radiation therapy and healthy cells. The fatty acids incorporate into cell membranes and act as a protective layer, reducing the direct harmful impact of therapy on healthy cells while allowing the therapy to maintain its anti-cancer effectiveness

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If high dosages of chemotherapy are used to improve treatment effectiveness, then cancer cell killing is enhanced, but side effects on healthy cells increase

Engineering Contradiction:
Improveeffectiveness of chemotherapyVSAvoidtherapy-induced toxicity
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent administers omega-3 fatty acids before chemotherapy cycles to pre-load cell membranes with protective lipids. This preliminary incorporation allows healthy cells to better withstand high-dose chemotherapy, enabling more aggressive treatment regimens without proportionally increasing side effects

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent changes the biochemical composition parameter of cell membranes by increasing omega-3 fatty acid content through supplementation. This parameter change alters the physical and chemical properties of cell membranes, making them more resistant to chemotherapy-induced damage and allowing higher effective dosages

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The administration of omega-3 fatty acids enhances the effectiveness of chemotherapy or radiation therapy while reducing side effects, allowing for potentially lower dosages of cancer treatments and improving patient tolerability and overall survival.

Implementation Method 1

by incorporating these fatty acids into cell membranes, thereby protecting healthy cells from therapy-induced toxicity

Methodology Applied
Scientific EffectAbsorption: Absorption (physical)

Data Source

PatentEP2611439B1Composition comprising a combination of DHA and epa for parenteral administration prior to commencement of chemotherapy
Publication Date: 2018.02.21 FRESENIUS KABI DEUTSCHLAND GMBH
  • EP2611439B1 patent drawingFigure 1
  • EP2611439B1 patent drawingFigure 2
  • EP2611439B1 patent drawingFigure 3

AI summary

The invention relates to a composition comprising a combination of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The composition can be used for enhancing the activity of chemotherapy or radiotherapy and/or in the prevention or reduction of side effects caused by the chemotherapy or radiotherapy in a patient ill with cancer, the composition being intended for administration to the patient prior to the commencement of a cycle of chemotherapy or radiotherapy.